Transporter-Mediated Interaction Between Platinum Drugs and Sorafenib at the Cellular Level

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Platinum-based chemotherapy is a cornerstone for solid tumors.
• Sorafenib, a multikinase inhibitor, has shown limited benefit when combined with platinum drugs in clinical trials.
• Some studies report decreased survival with sorafenib and platinum combinations, particularly in ovarian and non-small cell lung cancers.

Purpose of the Study:

• To investigate the cellular mechanisms underlying the interaction between platinum drugs and sorafenib.
• To determine how sorafenib affects platinum accumulation and DNA platination in various cancer cell lines.

Main Methods:

• Combination index analysis to characterize drug interactions.
• Flameless atomic absorption spectrometry to quantify platinum accumulation.
• Western blot to assess protein expression, including Na+,K+-ATPase and copper transporter 1 (CTR1).

Main Results:

• Sorafenib downregulated Na+,K+-ATPase and CTR1 in platinum-sensitive ovarian (A2780) and lung (H520) cancer cells.
• This downregulation led to reduced cisplatin and carboplatin accumulation and decreased DNA platination.
• No similar effect was observed in platinum-resistant cell lines (A2780cis, H522) with lower transporter expression.
• An antagonistic interaction was consistently found between sorafenib and platinum drugs.

Conclusions:

• Sorafenib impairs platinum drug uptake by downregulating CTR1 and/or Na+,K+-ATPase.
• Reduced DNA platination by platinum drugs is a consequence of this impaired uptake.
• The observed antagonistic effect may explain the lack of clinical benefit and decreased survival in certain patient groups.